InsiderSignal.AI

InsiderSignal.ai

ABOS - Acumen Pharmaceuticals, Inc.

Insider Sale by Meisner Derek M (GC, Corp Sec)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

6 days ago, Meisner Derek M, serving as GC, Corp Sec at Acumen Pharmaceuticals, Inc. (ABOS), sold 9,406 shares at $3.01 per share, for a total transaction value of $28,311.00. Following this transaction, Meisner Derek M now holds 173,999 shares of ABOS.

This sale represents a 5.00% decrease in Meisner Derek M's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, February 27, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, March 3, 2026, 4 days after the trade was made.

Acumen Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Meisner Derek M

GC, Corp Sec

Derek M. Meisner is the Chief Legal Officer and Corporate Secretary at Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing treatments for Alzheimer's disease.[[1]](https://www.investing.com/news/insider-trading-news/meisner-acumen-pharmaceuticals-clo-sells-91k-in-abos-stock-93CH-4443422)[[4]](https://acumenpharm.com/portfolio-item/derek-meisner/) He joined Acumen in 2022, bringing over two decades of legal experience in regulatory compliance, financings, mergers and acquisitions, strategic partnerships, and corporate governance for public and private companies.[[4]](https://acumenpharm.com/portfolio-item/derek-meisner/) Prior to Acumen, Meisner held similar roles at X4 Pharmaceuticals, Inc. (as General Counsel) and Genocea Biosciences, Inc. (as Senior VP and General Counsel).[[2]](https://fintel.io/n/meisner-derek-m)[[3]](https://www.gurufocus.com/insider/48660/derek-m-meisner)[[4]](https://acumenpharm.com/portfolio-item/derek-meisner/) Earlier, he served as General Counsel for Boston-based financial services firms, including RA Capital Management, was a partner at K&L Gates, and worked as a Branch Chief in the U.S. Securities and Exchange Commission's Division of Enforcement.[[4]](https://acumenpharm.com/portfolio-item/derek-meisner/) As of early 2026, he owns approximately 83,800 shares of ABOS following recent sales under a Rule 10b5-1 plan totaling $91,073.[[1]](https://www.investing.com/news/insider-trading-news/meisner-acumen-pharmaceuticals-clo-sells-91k-in-abos-stock-93CH-4443422)[[2]](https://fintel.io/n/meisner-derek-m)

View full insider profile →

Trade Price

$3.01

Quantity

9,406

Total Value

$28,311.00

Shares Owned

173,999

Trade Date

Friday, February 27, 2026

6 days ago

SEC Filing Date

Tuesday, March 3, 2026

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Acumen Pharmaceuticals, Inc.

Company Overview

No company information available
View news mentioning ABOS

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4474351

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime